208 related articles for article (PubMed ID: 36924922)
1. Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders.
Konen FF; Möhn N; Witte T; Schefzyk M; Wiestler M; Lovric S; Hufendiek K; Schwenkenbecher P; Sühs KW; Friese MA; Klotz L; Pul R; Pawlitzki M; Hagin D; Kleinschnitz C; Meuth SG; Skripuletz T
Autoimmun Rev; 2023 May; 22(5):103312. PubMed ID: 36924922
[TBL] [Abstract][Full Text] [Related]
2. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
[TBL] [Abstract][Full Text] [Related]
3. Disease modifying therapies use associated with comorbid autoimmune diseases in multiple sclerosis patients.
Chouhfeh L; Kavak KS; Teter BE; Weinstock-Guttman B
Mult Scler Relat Disord; 2015 May; 4(3):228-33. PubMed ID: 26008939
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
[TBL] [Abstract][Full Text] [Related]
5. Increased prevalence of familial autoimmunity in simplex and multiplex families with juvenile rheumatoid arthritis.
Prahalad S; Shear ES; Thompson SD; Giannini EH; Glass DN
Arthritis Rheum; 2002 Jul; 46(7):1851-6. PubMed ID: 12124869
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune liver diseases in systemic rheumatic diseases.
Wang CR; Tsai HW
World J Gastroenterol; 2022 Jun; 28(23):2527-2545. PubMed ID: 35949355
[TBL] [Abstract][Full Text] [Related]
7. Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies.
Melamed E; Lee MW
Front Immunol; 2019; 10():2954. PubMed ID: 31998289
[TBL] [Abstract][Full Text] [Related]
8. Clustering of organ-specific autoimmunity: a case presentation of multiple sclerosis and connective tissue disorders.
Kale N; Icen M; Agaoglu J; Yazici I; Tanik O
Neurol Sci; 2008 Dec; 29(6):471-5. PubMed ID: 18854919
[TBL] [Abstract][Full Text] [Related]
9. Risk of venous thromboembolism in autoimmune diseases: A comprehensive review.
Menichelli D; Cormaci VM; Marucci S; Franchino G; Del Sole F; Capozza A; Fallarino A; Valeriani E; Violi F; Pignatelli P; Pastori D
Autoimmun Rev; 2023 Nov; 22(11):103447. PubMed ID: 37714419
[TBL] [Abstract][Full Text] [Related]
10. Osteopontin in autoimmune disorders: current knowledge and future perspective.
Xu C; Wu Y; Liu N
Inflammopharmacology; 2022 Apr; 30(2):385-396. PubMed ID: 35235108
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Economic Evaluation of Repository Corticotropin Injection: A Narrative Literature Review of Treatment Efficacy and Healthcare Resource Utilization for Seven Key Indications.
Philbin M; Niewoehner J; Wan GJ
Adv Ther; 2017 Aug; 34(8):1775-1790. PubMed ID: 28660550
[TBL] [Abstract][Full Text] [Related]
12. Different familial association patterns of autoimmune diseases between juvenile-onset systemic lupus erythematosus and juvenile rheumatoid arthritis.
Huang CM; Yang YH; Chiang BL
J Microbiol Immunol Infect; 2004 Apr; 37(2):88-94. PubMed ID: 15181489
[TBL] [Abstract][Full Text] [Related]
13. Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity.
Kunz M; Ibrahim SM
Mediators Inflamm; 2009; 2009():979258. PubMed ID: 19884985
[TBL] [Abstract][Full Text] [Related]
14. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
15. The pathogenic, therapeutic and diagnostic role of exosomal microRNA in the autoimmune diseases.
Mirzaei R; Zamani F; Hajibaba M; Rasouli-Saravani A; Noroozbeygi M; Gorgani M; Hosseini-Fard SR; Jalalifar S; Ajdarkosh H; Abedi SH; Keyvani H; Karampoor S
J Neuroimmunol; 2021 Sep; 358():577640. PubMed ID: 34224949
[TBL] [Abstract][Full Text] [Related]
16. IL-33 in autoimmunity; possible therapeutic target.
Yuan C
Int Immunopharmacol; 2022 Jul; 108():108887. PubMed ID: 35729828
[TBL] [Abstract][Full Text] [Related]
17. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.
Looney RJ
Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii13-ii17. PubMed ID: 15851522
[TBL] [Abstract][Full Text] [Related]
18. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
Freeman L; Longbrake EE; Coyle PK; Hendin B; Vollmer T
CNS Drugs; 2022 Dec; 36(12):1285-1299. PubMed ID: 36350491
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Autoimmune Disease: a Comparison of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Type 1 Diabetes.
Frazzei G; van Vollenhoven RF; de Jong BA; Siegelaar SE; van Schaardenburg D
Front Immunol; 2022; 13():899372. PubMed ID: 35844538
[TBL] [Abstract][Full Text] [Related]
20. [Multiple sclerosis and other autoimmune diseases].
Belniak E; Stelmasiak Z; Papuć E
Neurol Neurochir Pol; 2007; 41(3):259-66. PubMed ID: 17629820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
